Emboline, a privately held medical technology company focused on reducing stroke and ischemic damage during structural heart procedures such as transcatheter aortic valve replacement (TAVR), announced it has closed $20 Million in growth capital from Trinity Capital, a leading international alternative asset manager.

Emboline recently completed enrollment in the PROTECT H2H investigational device exemption (IDE) clinical trial (NCT05684146), a prospective randomized study evaluating the Emboliner Embolic Protection System. The funding will support Emboline's upcoming commercial launch activities and continued development of its embolic protection technology platform.